Datopotamab Deruxtecan Shows Durable Efficacy and Manageable Safety in HR+/HER2- Breast Cancer
December 15th 2022Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.
HD-ASCT Shows Longer Survival Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13th 2022An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Belantamb Mafodotin Shows PFS Benefit and Tolerable Safety in R/R Multiple Myeloma
December 12th 2022Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.
Dostarlimab Achieves Significant PFS Improvement in Primary Advanced or Recurrent Endometrial Cancer
December 2nd 2022The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.
FDA Grants FTD to Pelareorep Plus Atezolizumab and Chemotherapy for Advanced PDAC
December 2nd 2022The FDA has granted a fast track designation to the combination of pelareorep and atezolizumab with gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma after promising results were presented from the GOBLET study at the SITC Annual Meeting.
FDA Approves Olutasidenib for Relapsed/Refractory IDH1+ Acute Myeloid Leukemia
December 2nd 2022Positive and durable complete responses observed with olutasidenib in adult patient with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation have led the FDA to grant approval to the drug for this group of patients
FDA Grants Priority Review to Subcutaneous Epcoritamab for Previously Treated R/R LBCL
November 21st 2022Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.
Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLC
November 18th 2022Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.
Escalating Radiation Dose Shows Promise in Patients With Locally Advanced Pancreatic Cancer
November 17th 2022In an interview with Targeted Oncology, Michael Chuong, MD, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.
Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma
November 16th 2022In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.
Eganelisib Added to IMPASSION130 Doublet Improves Outcomes in Frontline mTNBC
November 15th 2022With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.
FDA Approves Tremelimumab With Durvalumab and Platinum Chemotherapy for mNSCLC
November 10th 2022The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.
FDA Advises Against an Approval Filing for Camidanlumab Tesirine to Treat R/R HL
November 10th 2022The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.
Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy
November 7th 2022Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.